Erasca Inc. has released a new corporate presentation detailing its progress in oncology drug development. The presentation highlights the company's industry-leading pipeline focused on shutting down the RAS/MAPK pathway, featuring candidates such as ERAS-0015, a pan-RAS molecular glue targeting RAS-mutated solid tumors, and ERAS-4001, a pan-KRAS inhibitor for KRAS-mutated solid tumors. Additional programs, including ERAS-007 and ERAS-601, are being evaluated in preclinical studies as potential combination therapies. Erasca reports a strong financial position with $362 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and outlines a cash runway into the second half of 2028. The company's leadership team and scientific advisory board include recognized experts in the field of cancer genetics and targeted therapy development. You can access the full presentation through the link below.